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“Personal” or “School” domain was eliminated, indicat-
ing the questionnaire is sensitive to the cultural and social
differences between Asian and European cultures. The re-
liability of the instrument as measured by Cronbach’s
alpha for the six domains for the diabetics ranges from
0.31 to 0.75.
CONCLUSION: Although the results appear improba-
ble, they agree with the cultural and social characteristics
of Singapore where the educational system is highly
stressful. Parents of diabetic children may have lower ex-
pectations of their children due to their condition, and
hence the perceived better QOL among the diabetic chil-
dren. However, more data needs to be collected to con-
firm this observation. *Maximum possible score of 100.
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OBJECTIVE: To highlight the effects incurred in the
pharmaco-utilization and in the total expenses for dys-
peptic patients by the introduction of a disease-manage-
ment guideline.
METHODS: A retrospective reading of an administrative
billing database in the Ravenna Local Health Unit was
performed for all health-assisted subjects of 10 GPs who
had previously developed and agreed to a clinical guide-
line to manage dyspeptic patients (Dyspro GPs) as well as
by a group of 30 self-regulated GPs (Control GPs). The
latter group was selected ex post so as not to be signifi-
cantly different from the former in terms of personal and
patient characteristics. According to anti-dyspeptic treat-
ment, patients were grouped as having had or not pre-
scriptions between 01/01/1999 and 12/31/1999. Dyspep-
tic subjects were divided as having had or not an earlier
anti-dyspeptic treatment (new users/users). The follow-up
period lasted 365 days.
RESULTS: A total of 51,904 subjects were enrolled, of
which 23.1% were enrolled by the Dyspro GPs and
76.9% by the Control GPs. The percentage of dyspeptic
patients accounted for 17.6% and 15.0% respectively of
subjects enrolled by the Dyspro GPs and the Control
GPs. The average age of dyspeptic patients was 57.1 
18.6 years and 57.3  18.9 years (p  ns) and the per-
centage of males was 40.1 and 42.0 (p  ns), respectively
in the Dyspro GPs and Control GPs groups. The average
drug costs for new users (35.76 vs 38.56) and users
(107.51 vs 113.73) was higher as was the average
hospitalization cost for new users (65.78 vs 70.84)
and users (61.13 vs 87.40) in patients enrolled by the
Control GPs. Casualty department access and gas-
troscopies were not different among patients enrolled by
the physician groups.
DISCUSSION: Pharmaceutical and hospital expenditures
decreased as a consequence of the introduction of a dis-
ease-management guideline.
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OBJECTIVE: Rabeprazole (Pariet) is a new proton-pump
inhibitor, which offers fast and consistent acid control.
Randomized controlled studies showed that rabeprazole
in active peptic ulcer is comparable to omeprazole and
more effective than ranitidine. We performed economic
evaluations of rabeprazole, omeprazole and ranitidine in
active gastric and duodenal ulcers.
METHODS: A decision tree model (DATA 3.0 Treeage
Software Inc.) was applied for retrospective analysis of
peptic ulcer healing rate in controlled clinical trials of the
three drugs. Direct costs of standard treatment in a hospi-
tal setting (six and four weeks for gastric and duodenal
ulcers respectively) were calculated. They included hospi-
tal bills, investigations and drug-acquisition costs. Cost-
minimization and cost-effectiveness analyses were used to
evaluate rabeprazole vs. omeprazole and rabeprazole vs
ranitidine respectively. To calculate the incremental cost-
effectiveness ratio, we utilized the rate of improvement in
well-being after two weeks of treatment.
RESULTS: The direct costs of rabeprazole and ranitidine
in active duodenal ulcer were comparable ($261,21 vs
$263,28), but the proton pump inhibitor was signifi-
cantly more cost-effective than the H2-blocker (incre-
mental cost-effectiveness ratio 0,43 vs 4,66). The differ-
ence was due to the higher healing rate and faster effect
of rabeprazole. The direct costs of rabeprazole and ome-
prazole in active duodenal and gastric ulcer were
$248,21 vs $266,94 and $311,53 vs $332,77 respec-
tively. The difference was due to lower acquisition cost of
rabeprazole.
CONCLUSION: Rabeprazole may offer economic ad-
vantages over omeprazole and ranitidine in hospital
treatment of active gastric and duodenal ulcers.
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OBJECTIVE: Proton pump inhibitors (PPIs) are an effec-
tive and safe treatment for healing GERD-related reflux
esophagitis. What remains unclear is whether there are
significant clinical and economic differences between the
PPIs for this type of indication. We conducted an eco-
nomic analysis comparing the newer PPIs to standard ref-
erence treatments based on the most commonly pre-
scribed PPI (omeprazole) and H2-blocker (ranitidine).
METHODS: We combined relative-healing-rate data
taken from a meta-analysis of head-to-head studies, with
similarly published data for omeprazole and ranitidine.
Using wholesale drug prices, we considered the difference
in treatment cost and success for each PPI compared to
omeprazole and ranitidine. Sensitivity analyses were con-
ducted using 95% confidence intervals around relative ef-
fect sizes and treatment failure costs.
RESULTS: Esomeprazole was the only PPI with statis-
tically significant differences to omeprazole, with 24 ad-
ditional healings per 1000 treated patients, at a cost per
additional healing of US$340. Introducing additional
costs, of over US$600 linked to managing treatment fail-
ures, resulted in esomeprazole dominating omeprazole.
Lansoprazole also showed additional benefit with a
lower cost, but failed to reach significant levels. Panto-
prazole and rabeprazole had slightly less treatment suc-
cess with a lower cost, but again confidence intervals
were wide. Compared to H2-blockers, all PPIs provided
significant additional benefits at a cost per healed patient
of US$200 to US$600, depending on the form of H2-
blocker. PPIs dominated once treatment-failure costs
were included.
CONCLUSION: Our study shows that over an eight-
week treatment period, esomeprazole is the only PPI that
is significantly distinguished from omeprazole in terms of
its clinical and economic effects. Our analysis also sug-
gests that PPI treatment is cost-effective compared to H2-
blockers, irrespective of the choice of PPI. Importantly,
omeprazole is soon to go off patent, and this is likely to
significantly reduce the incremental cost-effectiveness of
the newer PPIs.
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OBJECTIVES: Pharmaceutical spending control is a ma-
jor objective for most governments. The introduction of
new drugs is considered as a reason for increased spend-
ing, although often leading to actual savings. This study
aims to evaluate the effect that market penetration of es-
omeprazole (Nexium) will have on PPI pharmaceutical
expenditures in Greece.
METHODS: A model estimating drug budget savings po-
tentially achieved by replacing other PPIs with Nexium in
the Greek market has been developed based on clinical
trial results and market research data. This model is
based on current (MAT/5/2001) PPI sales data (IMS
data). For every marketed PPI, a “replacement ratio” for
each PPI according to indication is calculated. Then, a
“market penetration percentage” for Nexium is esti-
mated for a period of three years for every dosage form
and indication. Overall PPI costs with or without Nex-
ium are calculated for the Greek population according to
indication. The overall cost difference depicts potential
cost savings.
RESULTS: The predicted Greek annual expenditure in
public prices for PPIs without Nexium is approximately
GRD 27.2 billion. In indications which lead to expendi-
tures of GRD 23 billion, Nexium could be prescribed
leading to a potential reduction in PPI costs of approxi-
mately 15% of the predicted expenditure without Nex-
ium. Percentage cost-savings are higher if Nexium re-
places certain PPIs, like branded omeprazole and
pantoprazole. It can be seen that the expected expendi-
tures after Nexium are lower than current costs for all
PPIs. This holds across all doses for each of the PPIs. A
proportional reduction is expected in overall units sold,
measured in 28–pack equivalents. Sensitivity analyses
based on varying penetration rates do not alter initial re-
sults significantly.
CONCLUSION: Nexium offers a disease management
approach leading to actual cost savings in PPI expendi-
tures in Greece. The saving impact is greater if highly
priced PPIs are replaced.
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OBJECTIVE: Health state utilities (‘utilities’) based on
patient preferences associated with heartburn do not ex-
ist in the published literature. The objectives of our study
were to assess utilities in GERD patients with heartburn
in Germany and Sweden, and to analyze if the severity
and frequency of heartburn and other patient characteris-
tics may predict utilities.
METHODS: One thousand eleven GERD patients with
heartburn as the predominant symptom were recruited
by their physicians and interviewed over the telephone.
Utilities were assessed using the standard gamble (SG),
time trade-off (TTO), EuroQol, and rating scale (RS) in-
struments. Another RS was used to assess the utility as
the patients thought it would be without heartburn. Data
were also collected about the severity (mild, moderate,
severe) and the annual number of days with heartburn
(‘frequency’). Linear regression analysis was used to esti-
mate the prediction models.
